Human Tuberculosis Vaccine Market to Surpass US$ 69.39 Mn by 2030 - Coherent Market Insights

Global Human Tuberculosis Vaccine Market, by Route of Administration (Intradermal and Percutaneous), by Age Group (Pediatrics and Adults), by Distribution Channel (Public and Private) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 50.57 Mn in 2022 and is expected to exhibit a CAGR of 4.0% during the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.

Increasing prevalence of tuberculosis in children is expected to drive growth of global human tuberculosis vaccine market over the forecast period. For instance, according to a fact sheet published by the World Health Organization (WHO) in October 2021, around 1.1 million children were diagnosed with tuberculosis (TB) globally in 2020. TB in children is often overlooked by health providers and can be difficult to diagnose and treat. In 2020, globally the 30 high tuberculosis (TB) burden countries were accounted for 86% of new TB case, where eight countries from 30 countries accounted for two thirds of the total, with India leading the count, followed by China, Indonesia, the Philippines, Pakistan, Nigeria, Bangladesh, and South Africa.

Global Human Tuberculosis Vaccine Market – Impact of Coronavirus (COVID-19) Pandemic

The most recent pandemic is the coronavirus (COVID-19) pandemic, which was initially detected on December 31, 2019, in Wuhan, China. COVID-19 was declared a pandemic by the World Health Organization on March 11, 2020. According to the World Health Organization's Coronavirus Illness (COVID-19) Epidemiological Update, coronavirus disease (COVID-19) caused approximately 528 million cases and 6 million  fatalities globally, till May 31, 2022.

Furthermore, the COVID-19 pandemic is expected to have negative impact on the global human tuberculosis vaccine market growth, owing to increasing efficacy rate of influenza vaccine for treatment of covid infection during pandemic. For instance, in June, 2021, According to the World Health Organization (WHO) Global Tuberculosis Report 2021, case notifications have plummeted because of pandemic-related disruptions in healthcare services. For the first time in more than a decade, tuberculosis mortality has increased. Tuberculosis deaths have increased because of reduced access to care. In 2020, there were roughly 1.5 million tuberculosis deaths worldwide, representing the first year-over-year increase in tuberculosis deaths since 2005.

Browse 40 Market Data Tables and 48 Figures spread through 197 Pages and in-depth TOC on “Global Human Tuberculosis Vaccine Market”- Global Forecast to 2030, Global Human Tuberculosis Vaccine Market, by Route of Administration (Intradermal and Percutaneous), by Age Group (Pediatrics and Adults), by Distribution Channel (Public and Private), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa).

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/human-tuberculosis-vaccine-market-5209

Moreover, key companies in market are focusing on growth strategies such as partnership, which is expected to drive market growth over the forecast period. For instance, in July 2021, a Spain-based biopharmaceutical company Biofabri and The International AIDS Vaccine Initiative (IAVI), an international nonprofit research organization focused on developing vaccines and antibodies against infectious and neglected diseases, partnered to advance the tuberculosis vaccine candidate MTBVAC into efficacy trials

Key Takeaways of the Global Human Tuberculosis Vaccine Market:

• Global human tuberculosis vaccine market is expected to exhibit a CAGR of 4.0% during the forecast period, owing to increase in the prevalence of tuberculosis. For instance, according to data published by PubMed, a scientific journal, in March 2019, in Argentina, approximately 9,000 new cases of tuberculosis (TB) are recorded every year, representing an incidence rate of 22 cases per 100,000 inhabitants
• Major players operating in the global human tuberculosis vaccine market include GlaxoSmithKline Plc, Merck & Co., Inc., Serum Institute of India Pvt. Ltd., Valneva SE, Archivel Farma, BIOFABRI (Zendal), Japan BCG Laboratory, GreenSignal Bio Pharma Private Limited (GSBPL), AJ Vaccines A/S, Taj Pharma India Limited, and Biomed Lublin S.A..